Azad, Arun A.
Zoubeidi, Amina
Gleave, Martin E.
Chi, Kim N.
Article History
First Online: 16 December 2014
Competing interests
: A.A.A. declares honoraria from Janssen and receipt of research funding from Astellas. M.E.G. is listed as inventor on patent applications OGX 011 and OGX 427, submitted by the University of British Columbia, and licensed to OncoGenex Technologies, in which M.E.G. is a founding shareholder. K.N.C. declares receipt of research funding from Astellas, Janssen, Novartis and OncoGenex Technologies, and consultancy for Amgen, Astellas, Bayer, Janssen, Millennium, Novartis and Sanofi. A.Z. declares no competing interests.